Table 1 Baseline demographics and clinical characteristics of the 4 cohorts included in the study.

From: Large-scale deep learning analysis to identify adult patients at risk for combined and common variable immunodeficiencies

Characteristics

Cohort 1

Cohort 2

Cohort 3

Cohort 4

PI Cases (n = 797)

Controls (n = 797)

PI Cases (n = 797)

Controls (n = 797)

PI Cases (n = 2312)

Controls (n = 2312)

PI Cases (n = 19,924)

Controls (n = 19,924)

Age and Gender

Age (years)

46 ± 26

46 ± 25

46 ± 26

48 ± 24

44 ± 26

45 ± 24

47 ± 24

46 ± 23

18–30 (%)

16.39

16.32

16.98

17.02

17.12

17.14

13.89

14.01

31–50 (%)

24.55

24.61

23.96

23.91

23.65

23.69

28.98

29.79

51–70 (%)

35.85

35.79

36.05

35.85

34.81

34.79

35.76

36.03

71-max age (%)

23.21

23.28

23.01

23.22

24.43

24.38

21.37

20.17

Male (%)

46.9

46.3

46.6

45.4

44.3

41.7

38.7

37.8

Female (%)

53.1

53.7

53.4

54.6

55.7

58.3

61.3

62.2

Ethnicity (%)

Caucasian

82.4

85.1

83.4

88.1

81.7

84.2

85.3

86.8

African American

8.7

7.3

8.4

6.7

7.9

7.2

5.8

5.8

Asian

1.4

1.5

1.3

0.5

1.7

1.6

1.2

1.1

Other/Unknown

7.5

6.1

7

4.7

8.7

7.1

7.8

6.3

Patient History

Diagnosis History duration (years)a

10 (8–13)

12 (10–14)

10 (8–13)

12 (9–14)

9 (6–12)

11 (8–14)

9 (6–12)

11 (8–14)

Number of visitsa

201 (103–399)

145 (48–415)

206 (105–399)

182 (45–397)

108 (36–250)

73 (17–243.5)

87 (30–206)

64 (16–195)

  1. aMedian (25th–75th percentile).
  2. PI primary immunodeficiency.